{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:52:33Z","timestamp":1761897153651,"version":"3.37.3"},"reference-count":17,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10,22]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>MRD response has value as a prognostic factor for blinatumomab treatment in R\/R B-cell precursor ALL. MRD response was associated with better outcomes in terms of OS and RFS in blinatumomab-treated R\/R ALL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000457","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T13:42:44Z","timestamp":1571665364000},"page":"3033-3037","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["Molecular response with blinatumomab in relapsed\/refractory B-cell precursor acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"3","author":[{"given":"Nicola","family":"G\u00f6kbuget","sequence":"first","affiliation":[{"name":"Department of Medicine II, Goethe University, Frankfurt, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5514-5010","authenticated-orcid":false,"given":"Monika","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"University Schleswig Holstein in the City Hospital, Kiel, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony S.","family":"Stein","sequence":"additional","affiliation":[{"name":"City of Hope, Duarte, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf C.","family":"Bargou","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Mainfranken, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5454-6768","authenticated-orcid":false,"given":"Herv\u00e9","family":"Dombret","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Louis, University of Paris, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele K.","family":"Fielding","sequence":"additional","affiliation":[{"name":"UCL Cancer Institute, University College London, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Heffner","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Rigal-Huguet","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Toulouse, Toulouse, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark","family":"Litzow","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2481-7504","authenticated-orcid":false,"given":"Susan","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Zugmaier","sequence":"additional","affiliation":[{"name":"Amgen Research (Munich) GmbH, Munich, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[{"name":"Amgen, Inc., Washington, DC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Nagorsen","sequence":"additional","affiliation":[{"name":"Amgen, Inc., Thousand Oaks, CA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"City of Hope, Duarte, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max S.","family":"Topp","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,10,21]]},"reference":[{"issue":"2","key":"2019111521411101800_B1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11899-014-0210-9","article-title":"Pediatric-like therapy for adults with ALL","volume":"9","author":"Dombret","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"5","key":"2019111521411101800_B2","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J Clin Oncol"},{"year":"2014","author":"National Comprehensive Cancer Network","key":"2019111521411101800_B3"},{"issue":"4","key":"2019111521411101800_B4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"issue":"9","key":"2019111521411101800_B5","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"issue":"24","key":"2019111521411101800_B6","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1002\/cncr.25354","article-title":"Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"2019111521411101800_B7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"2019111521411101800_B8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111521411101800_B9","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/cncr.23819","article-title":"Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia","volume":"113","author":"O\u2019Brien","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"2019111521411101800_B10","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"G\u00f6kbuget","year":"2016","journal-title":"Haematologica"},{"issue":"26","key":"2019111521411101800_B11","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies","volume":"125","author":"van Dongen","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2019111521411101800_B12","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: A meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"24","key":"2019111521411101800_B13","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1200\/JCO.2008.16.1414","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children\u2019s Oncology Group study [published correction appears in J Clin Oncol. 2008;26(28):4697]","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111521411101800_B14","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1038\/leu.2008.227","article-title":"Minimal residual disease is an important predictive factor of outcome in children with relapsed \u201chigh-risk\u201d acute lymphoblastic leukemia","volume":"22","author":"Paganin","year":"2008","journal-title":"Leukemia"},{"issue":"11","key":"2019111521411101800_B15","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111521411101800_B16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/cncr.30264","article-title":"Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"123","author":"Jabbour","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"2019111521411101800_B17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.seminhematol.2008.09.003","article-title":"Treatment of adult acute lymphoblastic leukemia","volume":"46","author":"G\u00f6kbuget","year":"2009","journal-title":"Semin Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/20\/3033\/1496055\/advancesadv2019000457.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/20\/3033\/1496055\/advancesadv2019000457.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T23:54:31Z","timestamp":1573862071000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/20\/3033\/407210\/Molecular-response-with-blinatumomab-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,21]]},"references-count":17,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2019,10,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000457","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2019,10,21]]}}}